To explore the clinical efficacy of Fanbei Sanjie Granule assisted EGFR-TKI on advanced lung adenocarcinoma and effects on immune function. Methods:Clinical data of 90 cases with advanced lung adenocarcinoma that were treated in our hospital from February 2014 to February 2016 were studied. According to random number table, they were divided into control group and treatment group, with 45 cases in each group. The control group was treated with placebo in combination with gefitinib. The treatment group was treated with Fanbei Sanjie granules and EGFR-TKI targeting. The short-term curative effect, survival cycle, adverse reaction and quality of life improvement of the two groups were observed, and the expression level of immune function before and after treatment was observed. Results:After treatment, the effective rate and control rate of the treatment group were higher than those of the control group, and the difference was not significant (P>0.05). The stability rate of the treatment group was 55.55%, which was significantly higher than that of the control group (22.22%). There was significant difference between the two groups (P<0.05). There was no significant difference in the expression of immune function between the two groups before treatment (P>0.05). After treatment, the expression of immune function in the two groups was significantly improved (P<0.05), and the improvement of the expression of immune function in the observation group was significantly better than that in the control group (P<0.05). After treatment, the improvement rate of quality of life in the treatment group was 80%, which was significantly higher than that in the control group (35.55%), and there was significant difference between the two groups (P<0.05). The survival rate of the treatment group was 66.67% in the 24 months, which was significantly higher than that in the control group (33.33%) (P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion:Fanbei Sanjie Granule assisted EGFR-TKI targeting in treating advanced lung adenocarcinoma has significant curative effect, which can effectively improve the patient's immune function and quality of life, improve the survival cycle of patients, and reduce the adverse reactions.